PRKAB1 IDG kinase ARCHS4 coexpression (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with PRKAB1 IDG kinase ARCHS4 coexpression.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with PRKAB1 IDG kinase ARCHS4 coexpression.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with PRKAB1 IDG kinase ARCHS4 coexpression.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with PRKAB1 IDG kinase ARCHS4 coexpression.

Results found

Linked to

 

Label

Description

 

Gene

RNA polymerase II subunit J3

Gene

crystallin beta B2 pseudogene 1

Gene

killer cell immunoglobulin like receptor, three Ig domains X1 (pseudogene)

Gene

HERC2 pseudogene 5

Gene

mediator complex subunit 15 pseudogene 9

Gene

lymphocyte antigen 6 family member G5C

Gene

protein FAM153C

Gene

endothelin converting enzyme like 1 pseudogene 2

Gene

tubulin alpha 3f pseudogene

Gene

HERC2 pseudogene 8

  • Gene

    RNA polymerase II subunit J3


  • Gene

    crystallin beta B2 pseudogene 1


  • Gene

    killer cell immunoglobulin like receptor, three Ig domains X1 (pseudogene)


  • Gene

    HERC2 pseudogene 5


  • Gene

    mediator complex subunit 15 pseudogene 9


  • Gene

    lymphocyte antigen 6 family member G5C



  • Gene

    endothelin converting enzyme like 1 pseudogene 2


  • Gene

    tubulin alpha 3f pseudogene


  • Gene

    HERC2 pseudogene 8

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.